BioCentury | Mar 28, 2015
Clinical News

Northwest gains on GBM survival data

...tumors showed evidence of regrowth following six weeks of radiation and chemotherapy. Northwest spokesperson Jane Searle...
...Phase III trial of the autologous dendritic cells treated ex vivo with glioblastoma tumor fragments. Searle...
BioCentury | Jul 22, 2013
Company News

Imperial Innovations management update

...Imperial Innovations Group plc (LSE:IVO), London, U.K. Business: Finance, Other Departed: Susan Searle as CEO; she...
BioCentury | Jul 18, 2013
Company News

Searle leaves Imperial Innovations

...Imperial Innovations Group plc (LSE:IVO) said Susan Searle departed as CEO. She is succeeded by Russ...
BioCentury | May 13, 2013
Finance

Bile be gone

...and raising additional funds. LUM001 was discovered in the mid-1990s at G.D. Searle & Co. Pharmacia Corp. acquired Searle...
...is now a consultant to the firm. McKearn was formerly head of discovery research at Searle...
BioCentury | Apr 15, 2013
Clinical News

Searle preclinical data

...The agent suppressed inflammatory substances known to damage joints, such as interleukin-1, metalloproteinases, and prostaglandins. G.D. Searle & Co....
BioCentury | Apr 15, 2013
Company News

Shire Pharmaceuticals Group PLC, Recordati SpA deal

...countries. Urispas has annual U.K. sales of £1 million (US$1.7 million) SHP said. SHP appointed G.D. Searle & Co....
BioCentury | Sep 19, 2011
Emerging Company Profile

Galera: Replacing SOD

...compound was discovered in the early 1990s in the lab of Dennis Riley at the G.D. Searle & Co....
BioCentury | Dec 13, 2010
Finance

Imperial Ambitions

...year on June 30, the company had £23.7 million ($35.4 million). According to CEO Susan Searle...
...in more mature companies. Previously, Imperial had made only seed or series A investments, but Searle...
...far and then exit them through an existing industry player that can take them further," Searle...
BioCentury | Sep 20, 2010
Clinical News

Celebrex celecoxib COX-2 inhibitor regulatory update

...of care to reduce and regress adenomatous colorectal polyps in patients with familial adenomatous polyposis. G.D. Searle & Co....
BioCentury | Aug 31, 2009
Politics, Policy & Law

Doctoring the Lilly Doctrine

...what you've actually done," he said. The next landmark case was University of Rochester v. G.D. Searle & Co....
...a method of treating pain and inflammation by selectively inhibiting cyclooxygenase-2 (COX-2) but not COX-1. Searle...
...didn't have the chemistry capabilities to discover the compounds," Shuster said. Indeed, according to Shuster, Searle...
Items per page:
1 - 10 of 158
BioCentury | Mar 28, 2015
Clinical News

Northwest gains on GBM survival data

...tumors showed evidence of regrowth following six weeks of radiation and chemotherapy. Northwest spokesperson Jane Searle...
...Phase III trial of the autologous dendritic cells treated ex vivo with glioblastoma tumor fragments. Searle...
BioCentury | Jul 22, 2013
Company News

Imperial Innovations management update

...Imperial Innovations Group plc (LSE:IVO), London, U.K. Business: Finance, Other Departed: Susan Searle as CEO; she...
BioCentury | Jul 18, 2013
Company News

Searle leaves Imperial Innovations

...Imperial Innovations Group plc (LSE:IVO) said Susan Searle departed as CEO. She is succeeded by Russ...
BioCentury | May 13, 2013
Finance

Bile be gone

...and raising additional funds. LUM001 was discovered in the mid-1990s at G.D. Searle & Co. Pharmacia Corp. acquired Searle...
...is now a consultant to the firm. McKearn was formerly head of discovery research at Searle...
BioCentury | Apr 15, 2013
Clinical News

Searle preclinical data

...The agent suppressed inflammatory substances known to damage joints, such as interleukin-1, metalloproteinases, and prostaglandins. G.D. Searle & Co....
BioCentury | Apr 15, 2013
Company News

Shire Pharmaceuticals Group PLC, Recordati SpA deal

...countries. Urispas has annual U.K. sales of £1 million (US$1.7 million) SHP said. SHP appointed G.D. Searle & Co....
BioCentury | Sep 19, 2011
Emerging Company Profile

Galera: Replacing SOD

...compound was discovered in the early 1990s in the lab of Dennis Riley at the G.D. Searle & Co....
BioCentury | Dec 13, 2010
Finance

Imperial Ambitions

...year on June 30, the company had £23.7 million ($35.4 million). According to CEO Susan Searle...
...in more mature companies. Previously, Imperial had made only seed or series A investments, but Searle...
...far and then exit them through an existing industry player that can take them further," Searle...
BioCentury | Sep 20, 2010
Clinical News

Celebrex celecoxib COX-2 inhibitor regulatory update

...of care to reduce and regress adenomatous colorectal polyps in patients with familial adenomatous polyposis. G.D. Searle & Co....
BioCentury | Aug 31, 2009
Politics, Policy & Law

Doctoring the Lilly Doctrine

...what you've actually done," he said. The next landmark case was University of Rochester v. G.D. Searle & Co....
...a method of treating pain and inflammation by selectively inhibiting cyclooxygenase-2 (COX-2) but not COX-1. Searle...
...didn't have the chemistry capabilities to discover the compounds," Shuster said. Indeed, according to Shuster, Searle...
Items per page:
1 - 10 of 158